SG11201502430QA - Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates - Google Patents
Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugatesInfo
- Publication number
- SG11201502430QA SG11201502430QA SG11201502430QA SG11201502430QA SG11201502430QA SG 11201502430Q A SG11201502430Q A SG 11201502430QA SG 11201502430Q A SG11201502430Q A SG 11201502430QA SG 11201502430Q A SG11201502430Q A SG 11201502430QA SG 11201502430Q A SG11201502430Q A SG 11201502430QA
- Authority
- SG
- Singapore
- Prior art keywords
- cell
- ion exchange
- exchange membrane
- remove impurities
- binding agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261709871P | 2012-10-04 | 2012-10-04 | |
PCT/US2013/063503 WO2014055893A1 (en) | 2012-10-04 | 2013-10-04 | Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201502430QA true SG11201502430QA (en) | 2015-04-29 |
Family
ID=50435480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201502430QA SG11201502430QA (en) | 2012-10-04 | 2013-10-04 | Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150307596A1 (en) |
EP (1) | EP2903450A4 (en) |
JP (1) | JP2015535215A (en) |
CN (1) | CN105208876A (en) |
AU (1) | AU2013326897A1 (en) |
CA (1) | CA2886996A1 (en) |
HK (1) | HK1213148A1 (en) |
IL (1) | IL238111A0 (en) |
IN (1) | IN2015DN03203A (en) |
MX (1) | MX2015004258A (en) |
RU (1) | RU2015116883A (en) |
SG (1) | SG11201502430QA (en) |
WO (1) | WO2014055893A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2662096A1 (en) | 2005-08-24 | 2013-11-13 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
MX349210B (en) | 2009-06-03 | 2017-07-18 | Immunogen Inc | Conjugation methods. |
MX339927B (en) | 2011-03-29 | 2016-06-16 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process. |
WO2014055877A1 (en) | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
GB201616758D0 (en) * | 2016-10-03 | 2016-11-16 | Ge Healthcare Bio Sciences Ab | Novel chromatography media |
CN108549763B (en) * | 2018-04-09 | 2021-06-01 | 电子科技大学 | Charge exchange collision MCC method for numerical simulation of ion thruster |
CN118290514A (en) * | 2024-06-05 | 2024-07-05 | 东曜药业有限公司 | Method for purifying antibody-coupled drug based on anion membrane and antibody-coupled drug |
CN118290513A (en) * | 2024-06-05 | 2024-07-05 | 东曜药业有限公司 | Anion column chromatography method for removing free small molecules in antibody-coupled drug and antibody-coupled drug |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ533657A (en) * | 2002-01-03 | 2008-01-31 | Smithkline Beecham Corp | Methods for the preparation of immunoconjugates, in particular maytansinoids conjugated to a monoclonal antibody |
US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
EP2468304A3 (en) * | 2005-02-11 | 2012-09-26 | ImmunoGen, Inc. | Process for preparing stable drug conjugates |
EP2662096A1 (en) * | 2005-08-24 | 2013-11-13 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
MX349210B (en) * | 2009-06-03 | 2017-07-18 | Immunogen Inc | Conjugation methods. |
MX339927B (en) * | 2011-03-29 | 2016-06-16 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process. |
-
2013
- 2013-10-04 CA CA 2886996 patent/CA2886996A1/en not_active Abandoned
- 2013-10-04 SG SG11201502430QA patent/SG11201502430QA/en unknown
- 2013-10-04 MX MX2015004258A patent/MX2015004258A/en unknown
- 2013-10-04 US US14/430,744 patent/US20150307596A1/en not_active Abandoned
- 2013-10-04 JP JP2015535827A patent/JP2015535215A/en active Pending
- 2013-10-04 EP EP13843881.7A patent/EP2903450A4/en not_active Withdrawn
- 2013-10-04 WO PCT/US2013/063503 patent/WO2014055893A1/en active Application Filing
- 2013-10-04 CN CN201380061514.1A patent/CN105208876A/en active Pending
- 2013-10-04 IN IN3203DEN2015 patent/IN2015DN03203A/en unknown
- 2013-10-04 RU RU2015116883A patent/RU2015116883A/en not_active Application Discontinuation
- 2013-10-04 AU AU2013326897A patent/AU2013326897A1/en not_active Abandoned
-
2015
- 2015-04-02 IL IL238111A patent/IL238111A0/en unknown
-
2016
- 2016-02-04 HK HK16101358.6A patent/HK1213148A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20150307596A1 (en) | 2015-10-29 |
AU2013326897A1 (en) | 2015-05-07 |
JP2015535215A (en) | 2015-12-10 |
EP2903450A4 (en) | 2016-05-11 |
IN2015DN03203A (en) | 2015-10-02 |
CN105208876A (en) | 2015-12-30 |
WO2014055893A1 (en) | 2014-04-10 |
CA2886996A1 (en) | 2014-04-10 |
HK1213148A1 (en) | 2016-06-30 |
RU2015116883A (en) | 2016-11-27 |
IL238111A0 (en) | 2015-05-31 |
EP2903450A1 (en) | 2015-08-12 |
MX2015004258A (en) | 2015-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277652B (en) | Stable aqueous formulations of adalimumab | |
IL238111A0 (en) | Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates | |
ZA201605918B (en) | Preparation of cell-binding agent cytotoxic agent conjugates | |
IL268378A (en) | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates | |
HK1212701A1 (en) | Formulations of enzalutamide | |
HK1213174A1 (en) | Stable aqueous formulations of etanercept | |
SG10201609982PA (en) | Pharmaceutical formulations of tnf-alpha anitbodies | |
ZA201500212B (en) | Progesterone formulations | |
SI3336097T1 (en) | Preparation of the non-crystalline form of obeticholic acid | |
SG11201405605VA (en) | SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT | |
PL2908835T3 (en) | Stable formulations | |
EP2867199A4 (en) | Stable compositions of fesoterodine | |
EP2754451A4 (en) | The use of ache as nuclease | |
IL233879A0 (en) | Drypowder formulations of dnase i |